Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

被引：0

作者：

Siegel, C. ^{[1
]}

Danese, S. ^{[2
,3
]}

Rubin, D. T. ^{[4
]}

Sabino, J. ^{[5
]}

Long, M. D. ^{[6
]}

Cross, R. K. ^{[7
]}

Armuzzi, A. ^{[8
,9
]}

Blumenstein, I. ^{[10
]}

Kobayashi, T. ^{[11
]}

Lama, S. ^{[12
]}

Charles, L. ^{[12
]}

Cetin, V. ^{[12
]}

Petersen, A. ^{[12
]}

Wu, H. ^{[12
]}

Wang, D. ^{[13
]}

Jain, A. ^{[12
]}

D'Haens, G. ^{[14
]}

机构：

[1] Dartmouth Hitchcock Clin, Gastroenterol, Lebanon, NH USA

[2] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy

[3] Univ Vita Salute San Raffaele, Gastroenterol & Endoscopy, Milan, Italy

[4] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Inflammatory Bowel Dis, Chicago, IL USA

[5] Univ Hosp Leuven, Gastroenterol, Dept Gastroenterol, Leuven, Belgium

[6] Univ N Carolina, Chapel Hill, NC USA

[7] Univ Maryland, Sch Med, Gastroenterol & Hepatol, Baltimore, MD 21201 USA

[8] IRCCS Humanitas Res Hosp Rozzano, Inflammatory Bowel Dis, IBD Ctr, Milan, Italy

[9] Humanitas Univ Pieve Emanuele, Dept Biomed Sci, Milan, Italy

[10] Goethe Univ Hosp, Inflammatory Bowel Dis, Frankfurt, Germany

[11] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan

[12] Bristol Myers Squibb KK, Princeton, NJ USA

[13] Bristol Myers Squibb KK, Tokyo, Japan

[14] Amsterdam Univ Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP16

引用

页码：I100 / I101

页数：2

共 50 条

[1] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
Abreu, Maria T.
Danese, Silvio
Wolf, Douglas C.
Canavan, James B.
Jain, Anjali
Wu, Hsiuanlin
Petersen, AnnKatrin
Charles, Lorna
Afzali, Anita
Panaccione, Remo
GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
[2] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
Panaccione, R.
Danese, S.
Wolf, D. C.
Canavan, J. B.
Jain, A.
Wu, H.
Petersen, A.
Charles, L.
Afzali, A.
Abreu, M. T.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
[3] Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
Danese, Silvio
Panaccione, Remo
Abreu, Maria T.
Rubin, David T.
Ghosh, Subrata
Dignass, Axel
Afzali, Anita
Wolf, Douglas C.
Chiorean, Michael, V
Vermeire, Severine
Jain, Anjali
Charles, Lorna
Lawlor, Garrett
Osterman, Mark T.
Wu, Hsiuanlin
Canavan, James B.
Petersen, Annkatrin
Colombel, Jean-Frederic
Regueiro, Miguel
JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 264 - 274
[4] Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
Feagan, Brian G.
Matsuoka, Katsuyoshi
Rogler, Gerhard
Laharie, David
Vermeire, Severine
Danese, Silvio
Loftus Jr, Edward V.
Beales, Ian
Schreiber, Stefan
Kim, Hyo Jong
Faes, Margaux
de Haas, Angela
Masior, Tomasz
Rudolph, Christine
Peyrin-Biroulet, Laurent
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 563 - 584
[5] EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
Panaccione, Remo
Afzali, Anita
Hudesman, David
Lawlor, Garrett
Osterman, Mark T.
Eren, Devrim
Memaj, Arteid
Regueiro, Miguel D.
Ghosh, Subrata
GASTROENTEROLOGY, 2022, 162 (07) : S965 - S965
[6] Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
Armuzzi, Alessandro
Cross, Raymond K.
Lichtenstein, Gary R.
Hou, Jason
Deepak, Parakkal
Regueiro, Miguel
Wolf, Douglas C.
Akukwe, Lucy
Ahmad, Harris A.
Jain, Anjali
Kozinn, Marc
Wu, Hsiuanlin
Petersen, AnnKatrin
Charles, Lorna
Long, Millie
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) : 1067 - 1076.e3
[7] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
D'Haens, G.
Sands, B. E.
Ferrante, M.
Matsuoka, K.
Lindsay, J. O.
Blumenstein, I.
Mehra, D.
Charles, L.
Cetin, V.
Petersen, A.
Wu, H.
Wang, D.
Jain, A.
Hanauer, S. B.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1814 - I1815
[8] RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
Afzali, Anita
Chiorean, Michael V.
Lawlor, Garrett
Osterman, Mark T.
Eren, Devrim
Memaj, Arteid
Panaccione, Remo
Ghosh, Subrata
GASTROENTEROLOGY, 2022, 162 (07) : S229 - S229
[9] Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
Danese, S.
Colombel, J. F.
Ponich, T.
Jovanovic, I.
Bossuyt, P.
Longman, R.
Alekseeva, O.
Petersen, A.
Chitkara, D.
Marta, C.
Charles, L.
Rubin, D. T.
Afzali, A.
Loftus, E. V.
Wolf, D. C.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I094
[10] LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Wolf, Douglas C.
Colombel, Jean Frederic
Ponich, Terry P.
Jovanovic, Igor
Bossuyt, Peter
Longman, Randy
Alekseeva, Olga
Petersen, AnnKatrin
Chitkara, Denesh
Marta, Cecilia
Charles, Lorna
Rubin, David T.
Afzali, Anita
Loftus, Edward V.
Danese, Silvio
GASTROENTEROLOGY, 2022, 162 (07) : S969 - S969

← 1 2 3 4 5 →